Evidence map›Paper›PMID 34149808›Full record

ArticleFrontiers in genetics2021

A Scalable Strand-Specific Protocol Enabling Full-Length Total RNA Sequencing From Single Cells.

Simon Haile, Richard D Corbett, Veronique G LeBlanc, Lisa Wei, Stephen Pleasance, Steve Bilobram, Ka Ming Nip, Kirstin Brown, Eva Trinh, Jillian Smith and 13 more

Abstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Simon HaileCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Richard D CorbettCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Veronique G LeBlancCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Lisa WeiCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Stephen PleasanceCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Steve BilobramCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Ka Ming NipCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Kirstin BrownCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Eva TrinhCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Jillian SmithCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Diane L TrinhCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Miruna BalaCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Eric ChuahCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Robin J N CoopeCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Richard A MooreCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Karen L MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Yongjun ZhaoCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Martin HirstCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Samuel AparicioDepartment of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.
Inanc BirolCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Steven J M JonesCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Marco A MarraCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA sequencing (RNAseq) has been widely used to generate bulk gene expression measurements collected from pools of cells. Only relatively recently have single-cell RNAseq (scRNAseq) methods provided opportunities for gene expression analyses at the single-cell level, allowing researchers to study heterogeneous mixtures of cells at unprecedented resolution. Tumors tend to be composed of heterogeneous cellular mixtures and are frequently the subjects of such analyses. Extensive method developments have led to several protocols for scRNAseq but, owing to the small amounts of RNA in single cells, technical constraints have required compromises. For example, the majority of scRNAseq methods are limited to sequencing only the 3' or 5' termini of transcripts. Other protocols that facilitate full-length transcript profiling tend to capture only polyadenylated mRNAs and are generally limited to processing only 96 cells at a time. Here, we address these limitations and present a novel protocol that allows for the high-throughput sequencing of full-length, total RNA at single-cell resolution. We demonstrate that our method produced strand-specific sequencing data for both polyadenylated and non-polyadenylated transcripts, enabled the profiling of transcript regions beyond only transcript termini, and yielded data rich enough to allow identification of cell types from heterogeneous biological samples.

Indexed as

cellenONEfull-lengthRNAseqsingle-celltotal RNA

Identifiers

PMID34149808
PMCPMC8209500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.